A Boston-based clinical-stage CNS biotech that uses its proprietary NETSseq platform and machine learning to find drug targets in specific brain cell types, which now has a positive Phase III behind its lead Parkinson's disease drug.
A Boston-based clinical-stage CNS biotech that uses its proprietary NETSseq platform and machine learning to find drug targets in specific brain cell types, which now has a positive Phase III behind its lead Parkinson's disease drug.
